```html

Zollinger‑Ellison Syndrome (Gastrinoma with Metastasis)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (gastrinomas) develop, most often in the pancreas or duodenum. The excess gastrin stimulates the stomach lining to secrete large amounts of gastric acid, leading to severe peptic ulcer disease and, in many cases, metastatic spread to the liver or lymph nodes.

Although ZES can affect anyone, it most commonly appears in adults aged 30–60 years. The condition is extremely uncommon, with an estimated incidence of 0.1–0.3 cases per 100,000 people per year and a prevalence of roughly 1–3 per million worldwide.<sup>[1] Mayo Clinic</sup> About 20–25 % of patients have metastatic disease at the time of diagnosis.<sup>[2] NIH</sup>

Symptoms

Because the hallmark of ZES is hyperacidic gastric secretions, symptoms often mimic or exceed those of typical peptic ulcer disease. The following list includes both common and less‑frequent manifestations.

Gastrointestinal symptoms

• Recurrent or refractory peptic ulcers – multiple ulcers, often beyond the duodenum (e.g., jejunum, esophagus).
• Abdominal pain – crampy, usually epigastric, worsening 2–3 hours after meals.
• Diarrhea – watery, sometimes fatty (steatorrhea) due to acid‑induced inactivation of pancreatic enzymes.
• Heartburn / GERD – frequent reflux from excess acid.
• Nausea & vomiting – may be severe if ulcers bleed or cause obstruction.
• Weight loss – from malabsorption and decreased oral intake.
• Gastrointestinal bleeding – melena or hematemesis when ulcers erode vessels.

Systemic symptoms

• Fatigue – secondary to anemia, malnutrition, or chronic disease.
• Low‑grade fever – occasionally seen with extensive metastatic disease.
• Skin changes – rare, but can include flushing if the tumor produces other hormones.

Symptoms related to metastasis

• Liver enlargement or right‑upper‑quadrant pain – hepatic metastases are the most common site.
• Jaundice – when liver lesions obstruct bile flow.
• Back or flank pain – from metastatic lymph nodes.

Causes and Risk Factors

ZES is primarily a neuroendocrine tumor disease. Two major etiologic categories exist:

1. Sporadic gastrinomas

Approximately 70–80 % of cases occur without an identifiable inherited syndrome. The exact trigger for sporadic tumor formation is unknown, but likely involves somatic mutations in the MEN1 gene, p53, or KRAS pathways.

2. Hereditary (MEN1) syndrome

Up to 25 % of patients have multiple endocrine neoplasia type 1 (MEN1), an autosomal‑dominant disorder caused by germline mutations of the MEN1 tumor‑suppressor gene. MEN1 carriers develop pancreatic endocrine tumors, parathyroid hyperplasia, and pituitary adenomas together with gastrinomas.

Risk factors

• Family history of MEN1 or other endocrine neoplasias.
• Age 30–60 (peak incidence).
• Male sex shows a slight predominance (≈55 % male).
• Chronic gastritis or H. pylori infection does not cause ZES, but can coexist and obscure diagnosis.

Diagnosis

Because ZES mimics more common ulcer disease, a high index of suspicion is essential, especially when ulcers are multiple, large, or refractory to standard therapy.

1. Laboratory tests

• Fasting serum gastrin – markedly elevated (>1000 pg/mL) in >80 % of cases. Levels >10× the upper limit of normal with gastric pH < 2 are diagnostic.
• Secretin stimulation test – gastrin rises >120 pg/mL after IV secretin (2 U/kg); highly specific for gastrinoma.
• Baseline gastric pH measurement (often <2).
• Other labs: CBC (anemia), liver function tests (if metastasis suspected), fasting glucose, and calcium (to screen for MEN1).

2. Imaging studies

• Multiphasic CT scan of the abdomen – detects primary tumor and liver metastases; sensitivity ~70 %.
• Contrast‑enhanced MRI – superior for liver lesions and pancreatic tail lesions.
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – highly sensitive for neuroendocrine tumors, especially metastatic disease.
• Endoscopic ultrasound (EUS) – excellent for small pancreatic or duodenal lesions (<2 cm).
• Upper endoscopy (EGD) – evaluates ulcer burden; biopsies rule out Helicobacter infection and malignancy.

3. Staging

Based on the AJCC (American Joint Committee on Cancer) TNM system, staging guides treatment decisions and prognosis. Key points:

• T1–T2: Tumor ≤2 cm, generally localized.
• T3–T4: Tumor >2 cm or invading adjacent structures.
• N0–N1: Regional lymph node involvement.
• M0–M1: Absence or presence of distant metastasis (most commonly liver).

Treatment Options

Management combines acid suppression, tumor control, and supportive care.

Acid‑blocking therapy (first line)

• Proton pump inhibitors (PPIs) – high‑dose omeprazole, esomeprazole, or pantoprazole 60–80 mg/day (or divided doses). PPIs are the most effective way to control acid hypersecretion and heal ulcers.
• H2‑receptor antagonists – can be added if PPIs are insufficient, but usually less effective.

Long‑term PPI use should be monitored for vitamin B12 deficiency, magnesium loss, and osteoporosis risk.<sup>[3] Cleveland Clinic</sup>

Surgical resection

• Curative intent – enucleation or pancreaticoduodenectomy (Whipple) for localized tumors.
• Debulking surgery – removal of >90 % of tumor burden improves symptom control even when metastases are present.
• Pre‑operative localization with EUS or ^68Ga‑DOTATATE PET is essential to plan the approach.

Medical therapies for unresectable or metastatic disease

• Somatostatin analogues (octreotide, lanreotide) – reduce gastrin secretion and may shrink tumor size.
• Targeted therapy – everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) for progressive neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells; shown to improve progression‑free survival.
• Chemotherapy – platinum‑based regimens (cisplatin + etoposide) used rarely, mainly for high‑grade neuroendocrine carcinomas.

Liver‑directed therapies (for hepatic metastases)

• Radiofrequency ablation or microwave ablation.
• Transarterial embolization (TAE) or chemoembolization (TACE).
• Liver transplantation – considered only in highly selected patients with limited disease and good functional status.

Lifestyle and supportive measures

• Small, frequent meals low in fat and spice to minimize ulcer irritation.
• Avoid NSAIDs, aspirin, and alcohol.
• Maintain adequate hydration; replace electrolytes if chronic diarrhea occurs.
• Bone health monitoring – calcium, vitamin D, and DEXA scanning every 2–3 years if on long‑term PPIs.

Living with Zollinger‑Ellison Syndrome (Gastrinoma with Metastasis)

Managing ZES is a lifelong partnership between you, gastroenterologists, endocrinologists, surgeons, and sometimes oncologists.

Medication adherence

• Take PPIs exactly as prescribed; timing matters – usually 30 minutes before breakfast and dinner.
• Set reminders for somatostatin analogue injections (often monthly).
• Bring a medication list to every appointment.

Nutrition

• Consume a balanced diet rich in protein and complex carbs; limit acidic foods (citrus, tomato) if they trigger symptoms.
• If diarrhea is problematic, consider a low‑fat diet and possibly pancreatic enzyme replacement (under physician guidance).
• Stay hydrated; use oral rehydration solutions if watery stools persist.

Regular monitoring

• Serum gastrin level check every 6–12 months (or sooner if symptoms change).
• Imaging (CT/MRI) every 12 months to assess tumor size and metastatic spread.
• Bone density test every 2–3 years if on high‑dose PPIs.
• Screen for MEN1‑associated tumors: calcium, parathyroid ultrasound, and pituitary MRI every 1–2 years.

Psychosocial well‑being

• Connect with support groups (e.g., Neuroendocrine Tumor Research Foundation).
• Consider counseling for coping with chronic illness.
• Maintain regular physical activity within tolerance – walking, swimming, or yoga can improve GI motility and mood.

Prevention

Because most cases are sporadic or genetically predetermined, true primary prevention is limited. However, risk reduction strategies include:

• Genetic counseling and testing for individuals with a family history of MEN1.
• Avoiding chronic use of gastric irritants (NSAIDs, heavy alcohol) which can exacerbate ulcer formation.
• Early evaluation of persistent or refractory ulcer disease to diagnose ZES before metastatic spread.

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems:

• Refractory peptic ulcer disease – risk of perforation and peritonitis.
• Upper gastrointestinal bleeding – may require endoscopic or surgical intervention.
• Severe malabsorption – chronic diarrhea, steatorrhea, weight loss, and nutritional deficiencies.
• Metastatic disease progression – liver failure, portal hypertension, or biliary obstruction.
• Gastric neuroendocrine (carcinoid) tumors – secondary to hypergastrinemia.
• Bone demineralization – long‑term acid suppression linked to osteoporosis.
• Psychological impact – chronic pain and disease burden can cause anxiety or depression.

When to Seek Emergency Care

---

References

1. Mayo Clinic. Zollinger‑Ellison syndrome. Updated 2023. https://www.mayoclinic.org
2. National Institutes of Health. Neuroendocrine Tumors Fact Sheet. 2022. https://www.cancer.gov
3. Cleveland Clinic. Long‑term use of proton pump inhibitors: risks and benefits. 2021. https://my.clevelandclinic.org
4. World Health Organization. WHO classification of tumours of the digestive system. 5th ed., 2020.
5. European Neuroendocrine Tumor Society (ENETS) Guidelines for the Management of Gastrinomas. 2022.

```